h5n1 inactivated vaccine

The **h5n1 inactivated vaccine** is a non-infectious, monovalent, split-virion vaccine formulated for active immunization against disease caused by the highly pathogenic avian influenza A virus (H5N1 subtype)[1][5]. It is supplied with an adjuvant (such as MF59 in AUDENZ or AS03 in Q-Pan H5N1) to enhance the immune response, and is designed for rapid deployment in pandemic scenarios and for people at increased risk of exposure[1][5][4]. The antigen is manufactured using cell-based processes or other advanced recombinant techniques[1][5]. The primary mechanism is to induce protective immunity against the H5N1 virus by eliciting antibody responses against its hemagglutinin (HA) glycoprotein[2][3][5]. Developers and manufacturers include Seqirus (for AUDENZ) and GSK (for Q-Pan H5N1/Pumarix)[1][5]. Vaccines are included in national pandemic stockpiles and are approved for use in persons 6 months and older[5][6].

Brand names

AUDENZPumarix

Other names

H5N1 vaccineH-5N1 vaccineH 5N1 vaccineInfluenza Virus Vaccine, H5N1